Jieer Ying
Zhejiang Cancer Hospital
5
5
1
N/A
0
3
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+8 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Haijiao Yan
The First People's Hospital of Changzhou
Shared therapeutic areas:
Worked with same sponsors:
Haiping Jiang
First Affiliated Hospital of Zhejiang University
Shared therapeutic areas:
Worked with same sponsors:
chunmei Bai
Peking Union Medical College Hospital
Shared therapeutic areas:
Worked with same sponsors:
Liang Liu
Zhongshan Hospital Affiliated with Fudan University
Shared therapeutic areas:
Worked with same sponsors:
Deliang Fu
Huashan Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jing Dai
Zhongnan Hospital
Shared therapeutic areas:
Worked with same sponsors:
Shiwei Guo
Changhai Hospital
Shared therapeutic areas:
Worked with same sponsors:
Rushen Zhao
Zibo Municipal Hospital
Shared therapeutic areas:
Worked with same sponsors:
Ning Wu
Shanghai Pudong New District Gongli Hospital
Shared therapeutic areas:
Worked with same sponsors:
Wenhai Huang
Jinshan Hospital Affiliated to Fudan University
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma
Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
All 5 trials loaded